Traditionally slower, the summer of 2015 has not been the norm for penny stocks. Typically as more go on vacation, the markets slow down but for small cap stocks and micro cap stocks it would seem that the markets are just starting to heat up. With many of the markets leaning toward biotech stocks and marijuana stocks, many of today’s traders are finding success in many other sectors. For instance Enviro-Serv Inc (OTCMKTS: EVSV) focuses on pest control in the southern part of the United States, Hangover Joes’ Holdings (OTCMKTS:HJOE) has built a business around hangover remedies, and Trans-Pacific Aerospace Company, Inc. (OTCMKTS:TPAC) is billing itself as a mover in the aerospace industry.
Have you seen which traders are capturing the most gains from picks like these?
But this isn’t to say that biotechnology stocks and cannabis stocks are taking a back seat. Over the last few trading days, attention has mounted around Biolase, Inc.(NASDAQ:BIOL)’s most recent turn around in share price. The company even went as far to put out press and discuss the recent share price decline. To much surprise the share price of BIOL ended up turning around during the week of June 8. BIOL saw a low on Friday of $1.31 and has bounced back by as much as 49% hitting highs of $1.95. FBEC Worldwide, Inc (OTCMKTS:FBEC) has also been building its share price over the most recent 4 weeks in the market. Identifying itself as a beverage company FBEC focuses on the development of a proprietary hemp infused energy shot called H.E.M.P. From a low price of $0.004, Monday’s mid day highs of $0.09 mark a rally of more than 2,150%. The Company was recently featured in an analyst report where it was given a Buy Rating and $0.20 price target by Stonebridge Capital (http://snip.ly/eEtC).
Aoxing Pharmaceutical (NYSE:AXN) has begun to see interest build within the market. The company is focused mainly on the pain market in China. Its buprenorphine/naloxone sublingual tablet is currently under review by the China Food & Drug Administration. Since Friday, shares of this biotech stock have moved up significantly from a price of $1.52 to highs on Monday 6/8 of $2.94.